Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2020

01-01-2020 | Breast Surgery | Rebuttal Letter

Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues—author's reply

Authors: Bernadette Anna Maria Heemskerk-Gerritsen, Maartje Joanneke Hooning

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Login to get access

Excerpt

Words can do a lot of harm. One wrong headline in the lay press, shared on social media, can lead to a lot of misery. Misery for the women who underwent preventive breast surgery in the past and now could read in the news that this drastic operation may have been unnecessary. Misery for all dedicated clinicians who had to reassure these women that they had made the right decision, and also frustration for all investigators involved in the original paper who saw their message being framed so wrongly. …
Literature
1.
Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI-M, Collée M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J, van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning MJ (2019) Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 177(3):723–733CrossRef
2.
Neven P, Punie K, Wildiers H, Willers N, Van Ongeval C, Van Buggenhout G, Legius E (2019) Risk-reducing mastectomy in BRCA carriers: survival is not the issue. Breast Cancer Res Treat
3.
Evans DG, Howell SJ, Howell A (2019) Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy? Fam Cancer 18(4):377–379CrossRef
Metadata
Title
Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues—author's reply
Authors
Bernadette Anna Maria Heemskerk-Gerritsen
Maartje Joanneke Hooning
Publication date
01-01-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05487-3

Other articles of this Issue 1/2020

Breast Cancer Research and Treatment 1/2020 Go to the issue

Epidemiology

Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer

Epidemiology

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications

Preclinical study

Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort

Preclinical study

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

Epidemiology

Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

Epidemiology

Research-based PAM50 signature and long-term breast cancer survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits